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Hyalinizing spindle cell tumor with giant rosettes. 
Note 
Low grade fibromyxoid sarcoma is a rare, low-grade 
malignant soft tissue neoplasm with a potential for 
local recurrences as well as distant metastases. 
Classification 
Note 
Low grade fibromyxoid sarcoma belongs to the group 
of fibroblastic/myofibroblastic soft tissue tumors. Two 
main subtypes have been recognized: classical low 
grade fibromyxoid sarcoma and low grade fibromyxoid 
sarcoma with giant collagen rosettes. 
Clinics and pathology 
Disease 
Low grade fibromyxoid sarcoma (LGFMS) 
Embryonic origin 
Cellular origin unknown, but presumably of 
mesodermal derivation. Tumor cells show fibroblastic 
differentiation. 
Etiology 
Unknown. No known risk factors. 
Epidemiology 
Low grade fibromyxoid sarcoma is supposed to be rare, 
but as it is difficult to diagnose the true incidence is 
unknown. Patients of any age may be affected, and the 
male: female ratio is 1:1. 
Clinics 
Low grade fibromyxoid sarcoma usually presents as a 
painless mass, typically in the proximal extremities. 
Pathology 
Classical cases of LGFMS display a mixture of 
hypocellular, collagen-rich areas and more cellular, 
myxoid areas. A characteristic feature is the whorling 
growth pattern, often seen at the transition from 
hypocellular to more cellular, myxoid areas. Mitotic 
figures are rare. A subset of LGFMS shows focal 
collagen rosettes. 
Treatment 
The only consensus treatment for low grade 
fibromyxoid sarcoma is surgical excision. 
Prognosis 
When radically excised, the prognosis is usually good. 
However, local recurrences have been reported in 
approximately 10% of the cases, and distant spreading 
occurs in 5-10% of the cases. 
Cytogenetics 
Note 
In the Mitelman Database of Chromosome Aberrations 
in Cancer (2004), 16 cases with clonal aberrations are 
included. 
Cytogenetics Morphological 
The chromosomal translocation t(7;16)(q33;p11) is a 
characteristic feature. A few cases contain a 
supernumerary ring as the sole chromosomal 
abnormality. Comparative genomic hybridization 
allowed to assess the chromosomal origin of a 
supernumerary ring chromosome in one case. The  
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analysis revealed gain of material from 7p14-pter, 
7q31-q33, and 16p. FISH experiments using contigs of 
BAC clones were performed in two cases of low grade 
fibromyxoid sarcoma carrying a t(7;16) abnormality. 
The analysis revealed that the breakpoints were located 
within BAC clones RP11-388M20 (AC009088) in band 
16p11.2, and RP11- 29B3 (AC022173) and RP11-
377B19 (AC009263) in band 7q33; all the examined 
clones gave split signals on the derivative 
chromosomes 7 and 16. The FISH results for 
chromosome 7 identified a breakpoint region 
containing a single gene (LOC155008), which is 
homologous to Drosophila Bbf-2, encodes a B-ZIP 
transcription factor and named BBF2H7 (BBF2 human 
homolog on chromosome 7). The data for chromosome 
16 suggested FUS as the other candidate target gene. 
Probes 
BAC clones RP11-388M20 (AC009088) and CTD-
2594M1 in band 16p11.2.BAC clones RP11- 29B3 
(AC022173), RP11-377B19 (AC009263) and CTD-
2375H21 in band 7q33. 
Genes involved and proteins 
Note 
The t(7;16)(q33;p11) in two cases of low grade 
fibromyxoid sarcoma fuses the FUS gene to CREB3L2 
(also named BBF2H7), a previously uncharacterized 
gene that is homologous to the Drosophila Bbf-2 gene. 
A further study of 59 low grade soft tissue tumors 
provided results indicating that this fusion gene is 
specific for LGFMS; all 12 fusion-positive cases in that 
series fulfilled the morphologic criteria for LGFMS, 
suggesting that reverse transcriptase polymerase chain 
reaction (RT-PCR) analysis for the detection of a 
FUS/CREB3L2 chimeric transcript may be a valuable 





Alternate symbols: BBF2H7, DKFZp586F2423, 
DKFZp686O19165. 
DNA / RNA 
The entire CREB3L2 gene spans more than 120 kb 
genomic DNA and is composed of 12 exons. Exon 1, 
containing the initiation codon ATG, is the largest (454 
bp), and exon 7 the smallest (59 bp). Exon 12 includes 
the termination TAA codon. Introns 1 and 9 are the 
largest (73132 bp) and smallest (281 bp), respectively. 
Using in silico analysis and RT-PCR methodology 
analysis, a 2400 bp cDNA was compiled containing a 
1560 bp open reading frame by Storlazzi et al. (2003). 
RT-PCR analysis on cDNAs from 24 human tissues 
showed that CREB3L2 is expressed in most of the 
examined tissues. The strongest expression was found 
in placenta, lung, spleen and intestine, and the weakest 
in heart, brain, skeletal muscle, thymus, colon and 
leukocytes. In fetal tissues, the weakest expression was 
detected in brain and heart. A splice variant, lacking 
exon 2, was found in placenta, spleen and fetal liver. 
Since northern blot analysis was not performed, the 
possibility of additional splice variants and the actual 
size of the normal CREB3L2 transcript is not 
determined yet. The cDNA clones with accession 
numbers BX649143 and BX648300 (5381 bp) indicate 
that the CREB3L2 mRNA might be longer than 7 kbp. 
Protein 
The 1560 bp open reading frame is coding for a 519 
amino acid protein with an estimated molecular weight 
of 57 kDa. The amino acid sequence spanning residues 
291-356 of the predicted human CREB3L2 protein 
contains a consensus B-ZIP domain highly similar to 
that in the CREB3L1 (OASIS), CREB3L3 (CREB-H), 
CREB3L4 (CREB4 or AIBZIP), CREB3 (LUMAN) 
and Drosophila Bbf-2 transcription factors with 80, 60, 
9, 56 and 71% identity, respectively. It also contains 
the amino acid sequence RRKKKEY that is exactly 
conserved among CREB, CREM, ATF1, ATF6 and 
CREBL1. The leucine zipper motif of BBF2H7 is 
similar to that in CREB-H and CREB4 (pattern L-X6-
C-X6-L-X6-L-X6-L-X6-L; Fig. 5). It contains six 
repeats and consists of five leucines and one cysteine at 
the second heptad position (amino acid 328) of the 
leucine zipper. Downstream of the B-ZIP domain, 
CREB3L2 also contains a hydrophobic region, which 
was predicted to be an a-helical transmembrane domain 
(position 376-397; 
GTCLMVVVLCFAVAFGSFFQGY). This structural 
feature is also seen in the other members of the family, 





Alternate symbols are: TLS, FUS1. The FUS gene is 
also rearranged in myxoid liposarcoma with 
t(12;16)(q13;p11), which leads to its fusion with 
DDIT3. In acute myeloid leukaemia with 
t(16;21)(p11;q22) and in Ewing sarcoma with 
t(16;21)(p11;q22) as well, FUS is fused to the ERG 
gene, and in angiomatoid fibrous histiocytoma FUS is 
fused to ATF1. 




Up to now, FUS/CREB3L2 chimeric transcripts were 
identified in 14 cases. The fusion points varied within 
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FUS, but clustered to exons 5, 6 and 7. Small intronic 
insertions were also seen at the junction. In CREB3L2, 
all the fusion points have been found within exon 5. 
Detection 
A detailed description of the RT-PCR protocols for 




The function of the FUS/CREB3L2 chimera is 
unknown but it is reasonable to assume that it will have 
similar consequences as the other FUS chimeric 
proteins in the cell. Thus, the B-ZIP-encoding domain 
of CREB3L2 comes under the control of the FUS 
promoter, which, in turn, may cause deregulation of 
genes normally controlled by CREB3L2. In addition, 
by fusing the B-ZIP domain of CREB3L2 to the N 
terminal part of FUS, the ability to dimerize with other 
members of the OASIS family could be affected. The 
FUS/CREB3L2 chimera might retain the ability, as do 
FUS/DDIT3 and FUS/ERG, to bind to RNA 
polymerase II via the N-terminal part of FUS but would 
lack the ability to recruit the transcription and 
translation factor Y-box binding protein-1 (YB-1) 
because of the replacement of the central and C-
terminal parts of FUS by CREB3L2. Consequently, 
RNA splicing mediated by YB-1 also would be 
expected to be inhibited. 
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